Cargando…
LDLR dysfunction induces LDL accumulation and promotes pulmonary fibrosis
Treatments for pulmonary fibrosis (PF) are ineffective because its molecular pathogenesis and therapeutic targets are unclear. Here, we show that the expression of low‐density lipoprotein receptor (LDLR) was significantly decreased in alveolar type II (ATII) and fibroblast cells, whereas it was incr...
Autores principales: | Shi, Xiangguang, Chen, Yahui, Liu, Qingmei, Mei, Xueqian, Liu, Jing, Tang, Yulong, Luo, Ruoyu, Sun, Dayan, Ma, Yanyun, Wu, Wenyu, Tu, Wenzhen, Zhao, Yinhuan, Xu, Weihong, Ke, Yuehai, Jiang, Shuai, Huang, Yan, Zhang, Rui, Wang, Lei, Chen, Yuanyuan, Xia, Jingjing, Pu, Weilin, Zhu, Honglin, Zuo, Xiaoxia, Li, Yisha, Xu, Jinhua, Gao, Fei, Wei, Dong, Chen, Jingyu, Yin, Wenguang, Wang, Qingwen, Dai, Huaping, Yang, Libing, Guo, Gang, Cui, Jimin, Song, Nana, Zou, Hejian, Zhao, Shimin, Distler, Jörg H.W., Jin, Li, Wang, Jiucun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8792399/ https://www.ncbi.nlm.nih.gov/pubmed/35083881 http://dx.doi.org/10.1002/ctm2.711 |
Ejemplares similares
-
Evaluation of the antifibrotic potency by knocking down SPARC, CCR2 and SMAD3
por: Ding, Weifeng, et al.
Publicado: (2018) -
Dissection of the mechanism of traditional Chinese medical prescription-Yiqihuoxue formula as an effective anti-fibrotic treatment for systemic sclerosis
por: Wu, Ting, et al.
Publicado: (2014) -
Two Novel Disease-Causing Mutations in the LDLR of Familial Hypercholesterolemia
por: Hu, Haochang, et al.
Publicado: (2021) -
The LDLR c.501C>A is a disease-causing variant in familial hypercholesterolemia
por: Hu, Haochang, et al.
Publicado: (2021) -
Enhancement of Zyxin Promotes Skin Fibrosis by Regulating FAK/PI3K/AKT and TGF-β Signaling Pathways via Integrins
por: Huang, Yan, et al.
Publicado: (2023)